A phase 1 study of K-912, nonrandomized, open label, dose escalation study in Japanese patients with solid tumors.

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222174

Enrollment

Registered

2013-08-18

Start date

2013-08-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumors

Interventions

investigational material(s) Generic name etc : K-912 INN of investigational material : Therapeutic category code : 423 Antitumor antibiotics and preparations Dosage and Administration for Investigati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with histologically or cytologically diagnosis of solid tumor Patients with solid tumor which is resistant to standard anti-tumor therapies, or which no appropriate treatment is available Patients with adequate organ functions Patients with 0 to 1 of ECOG Performance Status (P.S.) score Patients with 12 weeks or more life expectancy and so on

Exclusion criteria

Exclusion criteria: Patients with the severe complication Patients with brain metastasis accompanying clinical symptoms Patients with hematopoietic tumor Patients with active infections in need of treatment for systemic and so on

Design outcomes

Primary

Measure	Time frame
Dose limiting toxicity (DLT) CTCAE ver.4.0	—

Secondary

Measure	Time frame
Pharmacokinetics and anti-tumor activity RECIST ver.1.1, Drug concentration measurement	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026